Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2023-11-14 00:00:00 ET · period of report 2023-11-09 · accession 0001610717-23-000355 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-14 | 2023-11-09 | RVMD | Borisy Alexis | Dir | A - Grant | — | +2.09M | 2.33M | +872% | — |
| D | 2023-11-14 | 2023-11-09 | RVMD | Borisy Alexis | Dir | A - Grant | — | +296.0K | 296.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-09 | A | A | 2,091,672 | — | 2,331,494 | D | — | — | (F1) Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. (F2) Includes 5,200 restricted stock units. |
| 2 | Derivative | Earn-out Shares | 2023-11-09 | A | A | 296,039 | — | 296,039 | D | — · — to 2024-12-17 | 296,039 Common Stock | (F3) Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares. |